Detail of "77907-69-8"

Reference

High-dose interferon a-2a with ribavirin and amantadine in naive chronic hepatitis C patients - results of a randomized, prospective, pilot study

High-dose interferon a-2a with ribavirin and amantadine in naive chronic hepatitis C patients - results of a randomized, prospective, pilot study. Ullerich, H.; Avenhaus, W.; Poremba, C.; Domschke, W.; Menzel, J. ( Department of Medicine B, University of Muenster, Muenster, Germany). Alimentary Pharmacology and Therapeutics, 16(12), 2107-2114 (English) 2002 Blackwell Science Ltd. CODEN: APTHEN. ISSN: 0269-2813. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Background: Hepatitis C viral kinetic studies have demonstrated the increased anti-viral effect of higher than std. dosages of interferon and of daily treatment schedules. Aim: To compare, in a prospective, randomized, controlled trial, the efficacy and safety of high-dose interferon-a therapy vs. std.-dosage interferon-a therapy, in a triple therapy combination with ribavirin and amantadine. Methods: Previously untreated patients with chronic hepatitis C were randomized to the std. interferon-a group (n = 15), receiving thrice weekly 6 MU interferon-a for 12 wk, followed by 3 MU interferon-a for 36 wk, or the high-dose interferon-a group (n = 15), receiving daily 9 MU interferon-a for 4 wk, followed by 6 MU (weeks 5-8), 3 MU (weeks 9-12) and 1.5 MU (weeks 13-48) interferon-a. All patients were given ribavirin (1000-1200 mg) and amantadine (200 mg) daily for 48 wk. Results: At the end of treatment and after the 24-wk follow-up period, serum hepatitis C virus RNA was undetectable in eight (53%) and six (40%) patients treated with std. 36791-04-5 and 77907-69-8 which are cas registry numbers of chemicals are mentioned.-dosage interferon-a, resp., compared with 11 (73%) and 10 (67%) treated with high-dose interferon-a, resp. (not significant). The safety profile of both treatment regimens was similar. Severe adverse events leading to withdrawal from the study occurred in one patient (7%,) in each group, and in both groups one patient (7%) was lost during therapy for unknown reasons. Conclusions: The findings suggest that, although the difference between the response rates of std. and high-dose interferon-a regimens (within a triple antiviral therapy combination) did not reach statistical significance, there was a clear trend towards a higher response with high-dose interferon-a therapy and an equal safety profile. .

Effects of the CCR5-D32 mutation on antiviral treatment in chronic hepatitis C

Effects of the CCR5-D32 mutation on antiviral treatment in chronic hepatitis C. Ahlenstiel, Golo; Berg, Thomas; Woitas, Rainer P.; Grunhage, Frank; Iwan, Agathe; Hess, Lothar; Brackmann, Hans H.; Kupfer, Bernd; Schernick, Andrea; Sauerbruch, Tilman; Spengler, Ulrich (Medizinische Klinik u. Poliklinik I, Allgemeine Innere Medizin, Universitat Bonn, Bonn D-53105, Germany). Journal of Hepatology, 39(2), 245-252 (English) 2003 Elsevier Science B.V. 77907-69-8 and 98530-12-2 are also occured in this study. CODEN: JOHEEC. ISSN: 0168-8278. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 15 Background/Aims: The CC-chemokine receptor (CCR) 5-D32 mutation may predispose to chronic liver disease and high level viremia in hepatitis C. However, it is unclear whether CCR5-D32 also affects the response to antiviral treatment. Methods: the authors detd. CCR5 genotypes in patients with hepatitis C treated with either interferon-a (N=78) or interferon and ribavirin (N=78). In each group, rates of end of treatment responses (ETRs) and sustained virol. responses (SVRs) were compared between CCR5-D32 carriers and homozygous CCR5 wild type patients. Results: ETR and SVR were achieved in 25 and 12 patients with interferon-a and in 52 and 45 patients with interferon/ribavirin treatment, resp. CCR5-D32 carriers had significantly lower ETR rates than homozygous CCR5 wild type patients (10.5 vs. 39.0%; P=0.02), whereas SVR rates only showed a non-significant trend (5.3 vs. 18.6%). Multivariate anal. confirmed CCR5-D32 carriage as an independent neg. predictor for ETR in interferon-a monotherapy (odds ratio: 0.16; 95% confidence limits: 0.032-0.82; P=0.03). In interferon/ribavirin treated patients CCR-D32 carriers and CCR5 wild type patients had similar ETR rates [19.2% vs. 23.1%] and SVR rates [20.0% vs. 21.2%]. Conclusions: Response rates to interferon-a monotherapy are reduced in hepatitis C virus (HCV)-infected patients carrying the CCR5-D32 mutation. However, interferon/ribavirin combination treatment may overcome this neg. effect of CCR5-D32. .